Business
Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder
TORONTO, ON / ACCESSWIRE / May 10, 2022 / Novamind Inc.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company
About this update from Neuphoria Therapeutics Inc.
[{"type":"text","content":"TORONTO, ON / ACCESSWIRE / May 10, 2022 / Novamind Inc.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) (\"Novamind\" or the \"Company\"), a leading mental health company specialized in psychedelic medicine, today announced it has been selected to host a clinical trial for the acute treatment of social anxiety disorder (SAD), an understudied and common mental health condition that affects nearly 15 million American adults.1 The phase II randomized clinical study for the acute treatment of SAD (the \"PREVAIL Trial\") is sponsored by Bionomics Limited, a clinical-stage biopharmaceutical company (\"Bionomics\") (NASDAQ:BNOX) (ASX:BNO) and is currently enrolling patients at Novamind's Draper, Utah, research site.The PREVAIL Trial will examine the safety and efficacy of Bionomics' propriety drug candidate, BNC210, versus a placebo in reducing self-reported anxiety severity when participants take part in an anxiety-provoking behavioral task involving a speaking challenge. People with SAD experience extreme fear in social situations, when meeting new people or speaking in front of others, which can severely and negatively impact relationships, work and daily life. Current medical interventions include SSRIs, beta-blockers and anti-anxiety medications such as benzodiazepines.Dr. Reid Robison, Chief Medical Officer and Principal Investigator, commented: \"Social Anxiety Disorder is an understudied mental health condition and yet it's very common with widespread impact across multiple domains of life. Existing medications for social anxiety are slow to work or are fraught with adverse effects. It's exciting to participate in studying a drug with a novel mechanism like BNC210 that could offer patients an alternate treatment option.\"The PREVAIL Trial is the second Bionomics study hosted by Novamind. In 2021, the Company announced it was selected to host a phase IIb randomized clinical trial investigating BNC210 as a treatment for PTSD. BNC210 has Fast Track designations from the U.S. Food and Drug Administration for the treatment of both PTSD and SAD, a process designed to facilitate development and expedite the review of drugs that address an unmet medical need for serious conditions.Dr. Robison continued, \"Working with leading drug developers continues to advance critical mental health research through a variety of compounds and widens the spectrum of co...